#Pharmacology2

28 Mar 2026

GLP‑1 drugs may reduce substance use and harms

Researchers found that GLP‑1 receptor agonist drugs, used for type 2 diabetes and weight loss, were linked to lower risk of substance use disorders and fewer severe harms in US veterans. The team calls for clinical trials.

Read

Photo by Trey Gibson, Unsplash

27 Feb 2026

New inflammatory pathway may explain some rheumatoid arthritis treatment failures

A Washington State University study found that a lesser-known TWEAK–Fn14 pathway can join with TNF to increase inflammation. Blocking Fn14 reduced this surge and may explain why some patients do not respond to TNF inhibitors.

Level

Read

No more articles